Biomea Fusion, Inc. BMEA 深 滬
已收盤 08-01 16:00:00 美东时间
1.57
-0.090
-5.42%
華盛通- 最 高1.65
- 今 開1.64
- 成交量 106.04万股
- 最 低 1.53
- 昨 收 1.66
- 總市值 8952.50万
- 52周最高 13.07
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.2905
- 委 比 -74.00%
- 總股本 5702.23万
- 歷史最高 43.69
- 量 比 1.25
- 振 幅 7.23%
- 歷史最低 1.2905
- 每 手 1
- 風險率 3.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Biomea Fusion Appoints Julianne Averill to its Board of Directors
Biomea Fusion, Inc. has appointed Julianne Averill to its Board of Directors and the Audit Committee, effective July 22, 2025, succeeding Bihua Chen. Averill, a seasoned finance and strategy executive, brings over two decades of experience in life sciences and digital health. She currently serves as Managing Director at Danforth Advisors and specializes in capital markets, M&A, and organizational design. Averill holds an M.S. in Accountancy and i...
07-24 11:00
美股大行评级 | 潜在涨幅23.77%！美国运通获德银升目标价至375美元，维持"买入"评级
今日重点评级关注：德银：维持美国运通"买入"评级，目标价从371美元升至375美元；巴克莱：维持Gaming and Leisure Props"标配"评级，目标价从54美元升至55美元
07-22 09:35
Citigroup Maintains Buy on Biomea Fusion, Lowers Price Target to $9
Citigroup analyst Yigal Nochomovitz maintains Biomea Fusion (NASDAQ:BMEA) with a Buy and lowers the price target from $22 to $9.
07-16 22:44
Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)
Biomea Fusion announced new data on icovamenib, an oral menin inhibitor, at ADA 2025. Preclinical studies show icovamenib enhances glycemic control and weight loss when combined with low-dose semaglutide, while preserving lean mass. It also rescues human myotube atrophy ex vivo. In the Phase II COVALENT-111 trial, icovamenib achieved a 1.0% placebo-adjusted HbA1c reduction and a 55% increase in C-peptide at Week 26, demonstrating durable effects ...
06-23 11:00
Biomea Fusion Closes $37.1M Stock Offering
Biomea Fusion ( ($BMEA) ) has shared an update. On June 17, 2025, Biomea Fusion...
06-21 05:28
美股大行评级 | 潜在涨幅261.01%！瑞穗上调Immuneering目标价至10美元，维持"跑赢大市"评级
康托·菲茨杰拉德：维持Meta Platforms(META)"超配"评级，目标价从676美元升至807美元
06-19 09:23
Biomea Fusion sinks 25%, prices $40M stock offering
Clinical-stage diabetes and obesity company, Biomea Fusion (NASDAQ:BMEA) priced its previously announced underwritten public offering of 19.45M shares and accompanying warrants to buy the same numbe...
06-18 14:39
快讯 | Biomea Fusion Inc：每股普通股及随附的普通股认股权证的合计发行价格为2.00美元。
Biomea Fusion Inc: Combined Offering Price of Each Share of Common Stock and Ac...
06-18 11:15
Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates
Biomea Fusion announced positive preclinical results for BMF-650, an oral GLP-1 receptor agonist for obesity. In a 28-day study with obese cynomolgus monkeys, BMF-650 showed dose-dependent reductions in food intake and 12-15% weight loss. It outperformed another leading oral GLP-1 RA candidate. The compound was well-tolerated with no safety concerns. Biomea plans to submit an IND in late 2025 and initiate a Phase I trial in obese individuals shor...
06-18 11:00
Stocks to Watch: Biomea Fusion, Bitdeer Technologies
Unity Software(U.US) reported fourth-quarter financial results after the market...
06-18 07:28
